首页|替米沙坦联合硝酸山梨酯片对冠心病合并高血压患者左室射血分数、血清炎性因子水平的影响

替米沙坦联合硝酸山梨酯片对冠心病合并高血压患者左室射血分数、血清炎性因子水平的影响

Effect of telmisartan combined with sorbitan nitrate tablets on left ventricular ejection fraction(LVEF)and serum inflammatory factor levels in patients with coronary artery disease combined with hypertension

扫码查看
目的 观察分析替米沙坦联合硝酸山梨酯片对冠心病合并高血压患者左室射血分数(LVEF)、血清炎性因子水平的影响.方法 以2023年1月-2024年2月医院收治的冠心病合并高血压患者作为研究对象,选择其中采用替米沙坦+常规冠心病治疗的44例患者为对照组,同时选择替米沙坦联合硝酸山梨酯片+常规冠心病治疗的56例患者为观察组.观察两组患者LVEF水平、血清炎性因子水平及不良反应发生率.结果 两组患者治疗前LVEF水平和白介素-6(IL-6)、高敏C反应蛋白(hs-CRP)等炎性因子水平差异均无统计学意义(P>0.05).治疗15d、30d后,两组患者LVEF水平均逐渐升高,但观察组患者各时点的LVEF水平均高于对照组,组间差异均有统计学意义(P<0.05);治疗30d后,两组患者IL-6、hs-CRP水平均降低,但观察组患者各项血清炎性因子水平均低于对照组,差异均有统计学意义(P<0.05).治疗后,两组患者不良反应发生率相近,差异无统计学意义(P>0.05).结论 联用替米沙坦与硝酸山梨酯片治疗冠心病合并高血压患者,可明显改善患者LVEF水平,并能降低炎性反应,且安全性良好.
Objective To observe and analyze the effects of telmisartan combined with isosorbide dinitrate tablets on left ventricular ejection fraction(LVEF)and serum inflammatory factor levels in patients with coronary heart disease and hypertension.Method From January 2023 to February 2024,patients with coronary heart disease and hypertension admitted to the hospital were selected as the research subjects.Among them,44 patients who received telmisartan+conventional coronary heart disease treatment were selected as the control group,and 56 patients who received telmisartan combined with isosorbide dinitrate tablets+conventional coronary heart disease treatment were selected as the observation group.Observe the LVEF levels,serum inflammatory factor levels,and incidence of adverse reactions in two groups of patients.Results There was no statistically significant difference in LVEF levels and levels of inflammatory factors such as IL-6,hs-CRP between the two groups of patients before treatment(P>0.05).After 15 and 30 days of treatment,the LVEF levels of both groups of patients gradually increased,but the LVEF levels of the observation group were higher than those of the control group at all time points,and the differences between the groups were statistically significant(P<0.05);After 30 days of treatment,the levels of IL-6 and hs-CRP in both groups of patients decreased,but the levels of various serum inflammatory factors in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the incidence of adverse reactions in the two groups of patients was similar,and the difference was not statistically significant(P>0.05).Conclusion For patients with coronary heart disease and hypertension,the combination of telmisartan and isosorbide dinitrate tablets can significantly improve LVEF levels and inhibit the action of inflammatory factors,with good safety.

TimisartanSorbitan nitrate tabletsCoronary heart diseaseHypertension

王贺鑫

展开 >

102600 北京市仁和医院

替米沙坦 硝酸山梨酯片 冠心病 高血压

2024

现代养生
河北省医疗气功医院

现代养生

影响因子:1.355
ISSN:1671-0223
年,卷(期):2024.24(15)